50 studies found for:    ovarian cancer recurrence | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence
Condition: First Recurrence of Ovarian Cancer
Interventions: Procedure: Secondary citoreduction;   Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
2 Recruiting Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: pegylated liposomal doxorubicin;   Drug: Gemcitabine
3 Recruiting The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Condition: Ovarian Neoplasms
Intervention: Other: Determination of CA 125 and HE4, Computed tomography
4 Not yet recruiting HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma
Conditions: Epithelial Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions: Procedure: HIPEC;   Drug: Carboplatin
5 Recruiting Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
Conditions: Adnexal Mass;   Borderline Ovarian Epithelial Tumor;   Ovarian Clear Cell Tumor;   Ovarian Endometrioid Tumor;   Ovarian Neoplasm;   Ovarian Serous Tumor;   Recurrent Ovarian Carcinoma
Interventions: Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Valproic Acid
6 Recruiting Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: Hyperthermic intraperitoneal chemotherapy (HIPEC);   Drug: Carboplatin
7 Recruiting Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission
Conditions: Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention: Drug: Omega Nutrition cold-milled flaxseeds
8 Recruiting Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
Conditions: Low-grade Serous Ovarian Carcinoma;   Recurrent Invasive Borderline Serous Ovarian Cancer
Intervention:
9 Recruiting Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Condition: Ovarian Epithelial Cancer Recurrent
Interventions: Drug: bevacizumab and trabectedin;   Drug: bevacizumab, trabectedin and carboplatin
10 Recruiting Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer
Condition: Metastatic Ovarian Cancer
Intervention: Other: Experimental arm
11 Recruiting Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to First Platinum-Resistant Recurrence of Ovarian Tumor
Condition: First Platinum-resistant Recurrent of Epithelial Ovarian Cancer
Intervention: Device: Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin
12 Recruiting Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.
Condition: Ovarian Cancer
Interventions: Drug: Cabazitaxel;   Drug: Tocotrienol
13 Recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
14 Recruiting Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Conditions: Ovarian Epithelial Cancer Recurrent;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Procedure: Secondary Cytoreductive Surgery;   Drug: Salvage Chemotherapy
15 Recruiting Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Conditions: Advanced Malignant Neoplasm;   Cervical Squamous Cell Carcinoma;   Endometrial Carcinoma;   Malignant Uterine Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage III Bladder Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Bladder Cancer;   Stage IVA Cervical Cancer;   Stage IVB Bladder Cancer;   Stage IVB Cervical Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nanoparticle Albumin-Bound Rapamycin;   Other: Quality-of-Life Assessment
16 Recruiting Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Conditions: Ovarian Cancer;   Ovarian Neoplasms
Interventions: Biological: Vigil;   Biological: Placebo
17 Recruiting Biomarker Guided Treatment in Gynaecological Cancer
Condition: Endometrial Cancer
Interventions: Procedure: Biomarker (ER/PR) guided lymphadenectomy;   Drug: Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
18 Recruiting Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Procedure: ovarian cancer surgery
19 Not yet recruiting Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Carboplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
20 Recruiting p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Condition: Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Interventions: Drug: APR-246;   Drug: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years